Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

ENTA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Enanta Pharmaceuticals, Inc.NASDAQ: ENTA

Gross Margin · Q2 FY2026 · quarter ended Mar 2026

Gross margin narrows to 93.0%

Gross margin was 93.0% in Q2 FY2026, down 7.0 pp from a year earlier. On a trailing-twelve-month basis it was 98.3%, down 1.7 pp year over year. Over 3 fiscal years it narrowed by 7.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
93.0%-7.0 pp QoQ
Last fiscal yearSep 2025
93.0%-7.0 pp YoY
LTMMar 2026
98.3%-1.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.0 pp——
1 year-7.0 pp——
3 years-7.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
93.0%
Year-over-year change
-7.0pp

Gross Margin vs competitors

How ENTA compares with its peers on the latest reported figures

  • ENTA's LTM Mar 2026 gross margin of 98.3% is the 3rd highest of the 8 companies compared; the peer median is 82.6%.
  • Its year-over-year change of -1.7 pp is the 4th highest of 6, against a peer median of +2.3 pp.
  • Over three fiscal years its change of -7.0 pp compares with a peer median of -6.4 pp.
ENTA Competitors Peer median
Gross Margin for ENTA and competitors
Company Period LTM level YoY 3-year change
TNYATenaya Therapeutics, Inc.LTM Mar 2026144.9% ——
PYXSPyxis Oncology, Inc.LTM Mar 202699.8% ——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
ASMBAssembly Biosciences, Inc.LTM Mar 202677.2% +110.0 pp—
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding ENTA) 82.6%+2.3 pp-6.4 pp

Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue97.07M86.16M79.2M67.64M65.32M
Cost of Revenue00004.59M
Gross Profit97.07M86.16M79.2M67.64M60.74M
Gross Margin100.0%100.0%100.0%100.0%93.0%
Research & Development174.11M164.52M163.52M131.48M106.74M
Selling, General & Admin32.54M45.48M52.89M57.85M43.93M
Operating Expenses206.65M210M216.41M189.33M146.09M
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
EBITDA(104.25M)(119.22M)(123.48M)(104.51M)(70.78M)
EBITDA Margin-107.4%-138.4%-155.9%-154.5%-108.4%
Operating Income(109.57M)(123.84M)(137.21M)(121.69M)(85.35M)
Operating Margin-112.9%-143.7%-173.2%-179.9%-130.7%
Interest Income2.02M1.57M11.36M14.77M9.48M
Interest Expense005.15M10.94M7.68M
Other Income / Expenses1.99M1.66M6.21M3.9M1.8M
Income Before Tax(107.58M)(122.19M)(131M)(117.79M)(83.55M)
Pre-Tax Margin-110.8%-141.8%-165.4%-174.2%-127.9%
Income Tax Expense(28.58M)(433K)2.82M(1.74M)(1.66M)
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Net Margin-81.4%-141.3%-169.0%-171.6%-125.4%
EPS (Basic)(3.92)(5.91)(6.38)(5.48)(3.84)
EPS (Diluted)(3.92)(5.91)(6.38)(5.48)(3.84)
Weighted Avg Shares20.17M20.6M20.97M21.16M21.34M
Weighted Avg Shares (Diluted)20.17M20.6M20.97M21.16M21.34M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Intrinsic Alpha fair value

Locked

Current Price

$8.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.